O	0	3	The
O	4	12	Possible
O	13	23	Preventive
O	24	28	Role
O	29	31	of
B-intervention	32	42	Pregabalin
O	43	45	in
B-condition	46	60	Postmastectomy
I-condition	61	65	Pain
I-condition	66	74	Syndrome
O	74	75	:
O	76	77	A
O	78	84	Double
O	84	85	-
O	85	92	Blinded
O	93	103	Randomized
O	104	114	Controlled
O	115	120	Trial
O	120	121	.

O	122	129	Chronic
O	130	144	postmastectomy
O	145	149	pain
O	150	158	syndrome
O	159	160	(
O	160	164	PMPS
O	164	165	)
O	166	169	has
O	170	171	a
O	172	184	considerable
O	185	193	negative
O	194	200	impact
O	201	203	on
O	204	207	the
O	208	215	quality
O	216	218	of
O	219	223	life
O	224	226	of
O	227	233	breast
O	234	240	cancer
O	241	249	patients
O	249	250	.

O	251	254	The
O	255	264	objective
O	265	267	of
O	268	272	this
O	273	278	study
O	279	282	was
O	283	285	to
O	286	292	assess
O	293	296	the
O	297	305	possible
O	306	316	preventive
O	317	321	role
O	322	324	of
O	325	338	perioperative
O	339	349	pregabalin
O	350	352	in
O	353	357	PMPS
O	357	358	.

O	359	363	This
O	364	374	randomized
O	375	385	controlled
O	386	391	study
O	392	400	included
B-total-participants	401	404	200
B-eligibility	405	413	patients
I-eligibility	414	418	with
I-eligibility	419	425	breast
I-eligibility	426	432	cancer
I-eligibility	433	442	scheduled
I-eligibility	443	446	for
I-eligibility	447	455	elective
I-eligibility	456	462	breast
I-eligibility	463	469	cancer
I-eligibility	470	477	surgery
O	477	478	.

O	479	483	They
O	484	488	were
O	489	497	randomly
O	498	506	assigned
O	507	509	to
O	510	513	one
O	514	516	of
O	517	520	two
O	521	530	treatment
O	531	537	groups
O	537	538	.

O	539	542	The
O	543	553	pregabalin
O	554	559	group
O	560	568	received
O	569	571	75
O	572	574	mg
O	575	577	of
O	578	588	pregabalin
O	589	594	twice
O	595	600	daily
O	601	604	for
O	605	610	seven
O	611	615	days
O	616	619	and
O	620	623	the
B-control	624	631	control
I-control	632	637	group
O	638	646	received
O	647	651	oral
O	652	662	equivalent
O	663	670	placebo
O	671	679	capsules
O	679	680	.

O	681	684	The
O	685	692	primary
O	693	700	outcome
O	701	704	was
B-outcome-Measure	705	716	development
I-outcome-Measure	717	719	of
I-outcome-Measure	720	731	neuropathic
I-outcome-Measure	732	736	PMPS
O	736	737	.

O	738	749	Neuropathic
O	750	754	pain
O	755	758	was
O	759	767	assessed
O	768	773	using
O	774	777	the
O	778	785	Grading
O	786	792	System
O	793	796	for
O	797	808	Neuropathic
O	809	813	Pain
O	813	814	.

O	815	824	Secondary
O	825	832	outcome
O	833	841	measures
O	842	846	were
B-outcome-Measure	847	853	safety
O	854	857	and
O	858	864	Visual
B-outcome-Measure	865	873	Analogue
I-outcome-Measure	874	879	Scale
I-outcome-Measure	880	886	scores
O	886	887	.

B-outcome	888	899	Neuropathic
I-outcome	900	904	pain
O	905	908	was
O	909	922	significantly
O	923	927	less
O	928	936	frequent
O	937	939	in
O	940	943	the
O	944	954	pregabalin
O	955	960	group
O	961	969	compared
O	970	972	to
O	973	976	the
O	977	984	control
O	985	990	group
O	991	993	at
O	994	998	four
O	999	1004	weeks
O	1005	1006	(
O	1006	1007	P
O	1008	1009	=
O	1010	1011	0
O	1011	1012	.
O	1012	1015	005
O	1015	1016	)
O	1016	1017	,
O	1018	1020	12
O	1021	1026	weeks
O	1027	1028	(
O	1028	1029	P
O	1030	1031	=
O	1032	1033	0
O	1033	1034	.
O	1034	1037	002
O	1037	1038	)
O	1038	1039	,
O	1040	1043	and
O	1044	1046	24
O	1047	1052	weeks
O	1053	1054	(
O	1054	1055	P
O	1056	1057	<
O	1058	1059	0
O	1059	1060	.
O	1060	1063	001
O	1063	1064	)
O	1065	1080	postoperatively
O	1080	1081	.

B-outcome	1082	1086	PMPS
O	1087	1090	was
O	1091	1100	diagnosed
O	1101	1103	in
B-iv-bin-abs	1104	1106	11
O	1107	1115	patients
O	1116	1117	(
B-iv-bin-percent	1117	1119	11
I-iv-bin-percent	1119	1120	%
O	1120	1121	)
O	1122	1124	of
O	1125	1128	the
O	1129	1139	pregabalin
O	1140	1145	group
O	1146	1149	and
B-cv-bin-abs	1150	1152	29
O	1153	1161	patients
O	1162	1163	(
B-cv-bin-percent	1163	1165	29
I-cv-bin-percent	1165	1166	%
O	1166	1167	)
O	1168	1170	of
O	1171	1174	the
O	1175	1182	control
O	1183	1188	group
O	1189	1190	(
O	1190	1191	P
O	1192	1193	<
O	1194	1195	0
O	1195	1196	.
O	1196	1199	001
O	1199	1200	,
O	1201	1209	relative
O	1210	1214	risk
O	1214	1215	:
O	1216	1217	0
O	1217	1218	.
O	1218	1220	26
O	1220	1221	,
O	1222	1224	95
O	1224	1225	%
O	1226	1228	CI
O	1228	1229	:
O	1230	1231	0
O	1231	1232	.
O	1232	1234	12
O	1234	1235	-
O	1235	1236	0
O	1236	1237	.
O	1237	1239	56
O	1239	1240	)
O	1240	1241	.

O	1242	1244	At
O	1245	1248	the
O	1249	1254	three
O	1255	1261	follow
O	1261	1262	-
O	1262	1264	up
O	1265	1269	time
O	1270	1276	points
O	1276	1277	,
B-outcome	1278	1284	Visual
I-outcome	1285	1293	Analogue
I-outcome	1294	1299	Scale
I-outcome	1300	1306	scores
O	1307	1313	during
O	1314	1317	the
O	1318	1323	first
O	1324	1329	three
O	1330	1343	postoperative
O	1344	1349	weeks
O	1350	1354	were
O	1355	1365	comparable
O	1366	1368	in
O	1369	1373	both
O	1374	1380	groups
O	1381	1386	while
O	1387	1391	they
O	1392	1396	were
O	1397	1410	significantly
O	1411	1416	lower
O	1417	1419	in
O	1420	1423	the
O	1424	1434	pregabalin
O	1435	1440	group
O	1441	1443	at
O	1444	1445	4
O	1445	1446	,
O	1447	1449	12
O	1449	1450	,
O	1451	1454	and
O	1455	1457	24
O	1458	1463	weeks
O	1463	1464	.

O	1465	1470	These
O	1471	1474	two
O	1475	1481	groups
O	1482	1486	were
O	1487	1497	comparable
O	1498	1500	in
O	1501	1504	the
B-outcome	1505	1514	frequency
I-outcome	1515	1517	of
I-outcome	1518	1525	adverse
I-outcome	1526	1532	events
O	1533	1534	(
O	1534	1535	P
O	1536	1537	=
O	1538	1539	0
O	1539	1540	.
O	1540	1543	552
O	1543	1544	)
O	1544	1545	.

O	1546	1559	Perioperative
O	1560	1564	oral
O	1565	1575	pregabalin
O	1576	1578	75
O	1579	1581	mg
O	1582	1587	twice
O	1588	1593	daily
O	1593	1594	,
O	1595	1603	starting
O	1604	1606	at
O	1607	1610	the
O	1611	1618	morning
O	1619	1621	of
O	1622	1629	surgery
O	1630	1633	and
O	1634	1643	continued
O	1644	1647	for
O	1648	1651	one
O	1652	1656	week
O	1656	1657	,
O	1658	1663	could
O	1664	1670	reduce
O	1671	1674	the
O	1675	1684	frequency
O	1685	1687	of
O	1688	1702	postmastectomy
O	1703	1707	pain
O	1708	1716	syndrome
O	1716	1717	.
